TY - JOUR T1 - A viral perspective on worldwide non-pharmaceutical interventions against COVID-19 JF - medRxiv DO - 10.1101/2020.08.24.20180927 SP - 2020.08.24.20180927 AU - Jean-Philippe Rasigade AU - Anaïs Barray AU - Julie Teresa Shapiro AU - Charlène Coquisart AU - Yoann Vigouroux AU - Antonin Bal AU - Grégory Destras AU - Philippe Vanhems AU - Bruno Lina AU - Laurence Josset AU - Thierry Wirth Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/31/2020.08.24.20180927.abstract N2 - Quantifying the effectiveness of large-scale non-pharmaceutical interventions (NPIs) against COVID-19 is critical to adapting responses against future waves of the pandemic. Most studies of NPIs thus far have relied on epidemiological data. Here, we report the impact of NPIs on the evolution of SARS-CoV-2, taking the perspective of the virus. We examined how variations through time and space of SARS-CoV-2 genomic divergence rates, which reflect variations of the epidemic reproduction number Rt, can be explained by NPIs and combinations thereof. Based on the analysis of 5,198 SARS-CoV-2 genomes from 57 countries along with a detailed chronology of 9 non-pharmaceutical interventions during the early epidemic phase up to May 2020, we find that home containment (35% Rt reduction) and education lockdown (26%) had the strongest predicted effectiveness. To estimate the cumulative effect of NPIs, we modelled the probability of reducing Rt below 1, which is required to stop the epidemic, for various intervention combinations and initial Rt values. In these models, no intervention implemented alone was sufficient to stop the epidemic for Rt’s above 2 and all interventions combined were required for Rt’s above 3. Our approach can help inform decisions on the minimal set of NPIs required to control the epidemic depending on the current Rt value.Competing Interest StatementBL is currently active in groups advising the French government for which BL is not receiving payment.Funding StatementJPR received support from the FINOVI Foundation (grant R18037CC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBoth data and analysis code are available online at https://github.com/rasigadelab/covid-npi. https://github.com/rasigadelab/covid-npi ER -